Parkinson's Foundation Launches PD Trial Navigator, Connecting 2000+ Participants to Clinical Trials
The Parkinson's Foundation recently celebrated a significant advancement in Parkinson's disease (PD) research with the introduction of the PD Trial Navigator program. This innovative initiative is designed to streamline the recruitment of participants for clinical trials, specifically targeting individuals with Parkinson's disease. So far, the program has successfully identified over 2,000 potential participants for the NEULARK clinical trial, sponsored by Neuron23.
Dr. James Beck, Executive Vice President and Chief Scientific Officer at the Parkinson's Foundation, emphasized the importance of this milestone, stating that the PD Trial Navigator serves as a crucial bridge that connects those living with Parkinson's to vital clinical studies. He remarked, "The initial success in identifying individuals for the NEULARK trial is a testament to the power of our PD GENEration database combined with Neuron23’s precision tools. This collaboration has dramatically streamlined the prescreening process for this critical treatment."
Launched back in 2019, the PD GENEration Powered by the Parkinson's Foundation has been pivotal in offering genetic testing and counseling to over 30,000 individuals with Parkinson's. This initiative allows participants to grasp their genetic predispositions, empowering them to understand their risks and potential treatment pathways. The PD Trial Navigator program builds upon this foundation by further enhancing accessibility to personalized clinical trials, tailored to each person’s unique genetic profile.
Interesting data from a recent survey highlighted that nearly 85% of participants in the PD GENEration study expressed a keen interest in being contacted about future clinical trials, with a significant proportion (64%) also open to participating in telehealth trials.
The PD Trial Navigator offers potential trial participants personalized support through trained Trial Navigators. These professionals provide them with the necessary information regarding the clinical research process, addressing any questions they may have. Participants interested in exploring these opportunities are directly connected to clinical trial sites.
In partnership with Neuron23, the NEULARK trial aims to engage individuals with Parkinson's disease who have yet to start on dopamine medications but exhibit an overactive LRRK2 pathway—a condition found in over 30% of all people with PD. The PD Trial Navigator program has already identified over 2,000 genetically eligible participants, showcasing its broad geographic reach and scalability.
Dr. Arash Rassoulpour, Chief Operating Officer at Neuron23, underscored the significance of this effort, stating that understanding the underlying biology driving each individual's Parkinson's disease is vital for effective treatment. He mentioned, "By collaborating with the Parkinson's Foundation and PD GENEration, we aim to identify individuals whose conditions may be driven by LRRK2 biology, thus paving the way for their involvement in precision medicine research. Such initiatives are essential for fostering a new wave of targeted therapies to mitigate the progression of Parkinson's disease."
The overarching goal of the Parkinson's Foundation is to improve care quality for those suffering from Parkinson's and to propel research initiatives towards a definitive cure. For individuals interested in learning more about or enrolling in the PD GENEration program, the Foundation has made resources available at Parkinson.org/PDGENEration.
About the Parkinson's Foundation
The Parkinson's Foundation is dedicated to enhancing the quality of life for those affected by Parkinson's disease by advancing care and fostering research aimed at finding a cure. Since its establishment in 1957, the Foundation has invested over $513 million into Parkinson's research and clinical care, engaging with the global community for collective efforts against this disease. To stay connected, visit their website at Parkinson.org or reach out via social media and their helpline at 1-800-4PD-INFO (1-800-473-4636).
Understanding Parkinson's Disease
Parkinson's disease is a rapidly growing neurological disorder that impacts more than a million individuals in the United States alone. Characterized by a gradual loss of motor control, it encompasses symptoms such as tremors at rest, diminished facial expressions, along with non-motor manifestations including sleep disturbances, loss of smell, and depression. With no known cure and approximately 90,000 new cases emerging each year in the U.S., the need for research and effective treatments remains paramount.
Dr. James Beck, Executive Vice President and Chief Scientific Officer at the Parkinson's Foundation, emphasized the importance of this milestone, stating that the PD Trial Navigator serves as a crucial bridge that connects those living with Parkinson's to vital clinical studies. He remarked, "The initial success in identifying individuals for the NEULARK trial is a testament to the power of our PD GENEration database combined with Neuron23’s precision tools. This collaboration has dramatically streamlined the prescreening process for this critical treatment."
Launched back in 2019, the PD GENEration Powered by the Parkinson's Foundation has been pivotal in offering genetic testing and counseling to over 30,000 individuals with Parkinson's. This initiative allows participants to grasp their genetic predispositions, empowering them to understand their risks and potential treatment pathways. The PD Trial Navigator program builds upon this foundation by further enhancing accessibility to personalized clinical trials, tailored to each person’s unique genetic profile.
Interesting data from a recent survey highlighted that nearly 85% of participants in the PD GENEration study expressed a keen interest in being contacted about future clinical trials, with a significant proportion (64%) also open to participating in telehealth trials.
The PD Trial Navigator offers potential trial participants personalized support through trained Trial Navigators. These professionals provide them with the necessary information regarding the clinical research process, addressing any questions they may have. Participants interested in exploring these opportunities are directly connected to clinical trial sites.
In partnership with Neuron23, the NEULARK trial aims to engage individuals with Parkinson's disease who have yet to start on dopamine medications but exhibit an overactive LRRK2 pathway—a condition found in over 30% of all people with PD. The PD Trial Navigator program has already identified over 2,000 genetically eligible participants, showcasing its broad geographic reach and scalability.
Dr. Arash Rassoulpour, Chief Operating Officer at Neuron23, underscored the significance of this effort, stating that understanding the underlying biology driving each individual's Parkinson's disease is vital for effective treatment. He mentioned, "By collaborating with the Parkinson's Foundation and PD GENEration, we aim to identify individuals whose conditions may be driven by LRRK2 biology, thus paving the way for their involvement in precision medicine research. Such initiatives are essential for fostering a new wave of targeted therapies to mitigate the progression of Parkinson's disease."
The overarching goal of the Parkinson's Foundation is to improve care quality for those suffering from Parkinson's and to propel research initiatives towards a definitive cure. For individuals interested in learning more about or enrolling in the PD GENEration program, the Foundation has made resources available at Parkinson.org/PDGENEration.
About the Parkinson's Foundation
The Parkinson's Foundation is dedicated to enhancing the quality of life for those affected by Parkinson's disease by advancing care and fostering research aimed at finding a cure. Since its establishment in 1957, the Foundation has invested over $513 million into Parkinson's research and clinical care, engaging with the global community for collective efforts against this disease. To stay connected, visit their website at Parkinson.org or reach out via social media and their helpline at 1-800-4PD-INFO (1-800-473-4636).
Understanding Parkinson's Disease
Parkinson's disease is a rapidly growing neurological disorder that impacts more than a million individuals in the United States alone. Characterized by a gradual loss of motor control, it encompasses symptoms such as tremors at rest, diminished facial expressions, along with non-motor manifestations including sleep disturbances, loss of smell, and depression. With no known cure and approximately 90,000 new cases emerging each year in the U.S., the need for research and effective treatments remains paramount.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.